Literature DB >> 11762950

Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice.

G Schett1, S Hayer, M Tohidast-Akrad, B J Schmid, S Lang, B Türk, F Kainberger, S Haralambous, G Kollias, A C Newby, Q Xu, G Steiner, J Smolen.   

Abstract

OBJECTIVE: Rheumatoid arthritis is a prototype of a destructive inflammatory disease. Inflammation triggered by the overexpression of tumor necrosis factor alpha (TNFalpha) is a driving force of this disorder and mediates tissue destruction. Since matrix metalloproteinases (MMPs) are among the molecules activated by TNFalpha, we hypothesized that overexpression of their natural inhibitor, tissue inhibitor of metalloproteinases 1 (TIMP-1), in TNFalpha transgenic mice could inhibit the development of destructive arthritis.
METHODS: Systemic treatment was carried out by replication-defective adenoviral vectors for TIMP-1, beta-galactosidase, or phosphate buffered saline (PBS), which were applied once at the onset of arthritis. Clinical, serologic, radiologic, and histologic outcomes were assessed 18 days after the treatment.
RESULTS: The AdTIMP-1 group showed significantly reduced paw swelling and increased grip strength compared with the 2 control groups, whereas total body weight, TNFalpha, and interleukin-6 levels were similar in all 3 groups. Radiographic assessment revealed a significant reduction of joint destruction in the AdTIMP-1 group; this was confirmed by histologic analyses showing reduced formation of pannus and erosions in the AdTIMP-1 group compared with the AdLacZ and PBS control groups. The formation of arthritis-specific autoantibodies to heterogeneous nuclear RNP A2 was not observed in the AdTIMP-1 group but was present in the 2 control groups.
CONCLUSION: These results indicate a central role of MMPs in TNFalpha-mediated tissue damage in vivo and a promising therapeutic role for TIMP-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11762950     DOI: 10.1002/1529-0131(200112)44:12<2888::aid-art477>3.0.co;2-3

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

1.  Osteoclasts are essential for TNF-alpha-mediated joint destruction.

Authors:  Kurt Redlich; Silvia Hayer; Romeo Ricci; Jean-Pierre David; Makiyeh Tohidast-Akrad; George Kollias; Günter Steiner; Josef S Smolen; Erwin F Wagner; Georg Schett
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 2.  Lessons from animal models of arthritis.

Authors:  Wim B Van den Berg
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

3.  Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size.

Authors:  Robert D Gay; Adam W Clarke; Zehra Elgundi; Teresa Domagala; Raina J Simpson; Nga B Le; Anthony G Doyle; Phil A Jennings
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

4.  A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Sara E J Cotterell; Tracey L Mynott; Asiya Tschannerl; Patricia M A Gorak-Stolinska; Paul M Kaye
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 5.  Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.

Authors:  J Thomas Peterson
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

6.  Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model.

Authors:  Andrew D Rowan; Wang Hui; Tim E Cawston; Carl D Richards
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

7.  Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols.

Authors:  Eleni Douni; Petros P Sfikakis; Sylva Haralambous; Peter Fernandes; George Kollias
Journal:  Arthritis Res Ther       Date:  2003-11-07       Impact factor: 5.156

8.  Th2 and eosinophil responses suppress inflammatory arthritis.

Authors:  Zhu Chen; Darja Andreev; Katharina Oeser; Branislav Krljanac; Axel Hueber; Arnd Kleyer; David Voehringer; Georg Schett; Aline Bozec
Journal:  Nat Commun       Date:  2016-06-07       Impact factor: 14.919

Review 9.  Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics.

Authors:  Hideaki Nagase; Keith Brew
Journal:  Arthritis Res       Date:  2002-05-09

Review 10.  Autoantibodies in rheumatoid arthritis and their clinical significance.

Authors:  Günter Steiner; Josef Smolen
Journal:  Arthritis Res       Date:  2002-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.